Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression

Patrick Grierson, Danielle Crites, Marianna B. Ruzinova, Motoyo Yano, Kian Huat Lim

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

There are few effective therapies for unresectable or metastatic hepatocellular carcinoma. Recent data have demonstrated efficacy of immune checkpoint blockade in this difficult to treat disease; however, clinical experience is limited. We report a case of hepatocellular carcinoma displaying pseudoprogression followed by a late response with novel magnetic resonance imaging features following treatment with the anti-programmed cell death protein 1 agent pembrolizumab. (Hepatology Communications 2018;2:148–151).

Original languageEnglish
Pages (from-to)148-151
Number of pages4
JournalHepatology Communications
Volume2
Issue number2
DOIs
StatePublished - 2018

Fingerprint

Dive into the research topics of 'Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression'. Together they form a unique fingerprint.

Cite this